Clinical trials: SARS
Ovarian Reserve, SARS-CoV-2 Infection
Effect of Sars-cov-2 on Donor Oocyte Quality and Quantity, a Multicenter Retrospective Study.
Purpose: To determine the impact of SARS-CoV-2 infection and immunization on ovarian response to controlled ovarian stimulation (COS) and embryo development after in vitro fertilization (IVF) Methods: A retrospective multicentric…
- Conditions
- Ovarian Reserve, SARS-CoV-2 Infection, Blastocyst
- Trial name
- NCT05562479
- Testing
- Sars Cov 2 infection, Sars Cov 2 vaccination
- Where
- Colombia
- Volunteers
- 428 people, healthy volunteers welcome
- Sponsor
- Novafem
COVID19 Vaccination, Rituximab
Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.
Patients with treatment history of rituximab since 01.01.2019 and immunocompetent volunteers will be contacted to give a blood sample after their COVID19 vaccination, and in a subset also before vaccination.
- Conditions
- COVID19 Vaccination, Rituximab, Immunosuppression
- Trial name
- RituxiVac (NCT04877496)
- Testing
- History of exposure to anti-CD20 treatment since 01/01/2010, Completion of COVID19 vaccine at least 4 weeks ago
- Where
- Switzerland
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
SARS-CoV-2 Infection
EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)
Rapid antigen detection (RAD) tests are used to perform rapid diagnosis of SARS-CoV-2 infection based on a qualitative approach.
- Trial name
- WHO (NCT05618561)
- Testing
- EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test
- Where
- 5 sites in Croatia, Greece and 1 more
- Volunteers
- 599 people, healthy volunteers welcome
- Sponsor
- AnteoTech Ltd
Covid19
Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health Emergency of International Concern on…
- Trial name
- NCT04608305
- Testing
- IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime)
- Where
- 8 sites in Israel
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- Israel Institute for Biological Research (IIBR)
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Coronavirus Disease 2019, Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.
These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.
- Trial name
- NCT06291883
- Testing
- Kang Guan Recipe (Treat)
- Where
- Taiwan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sheng-Teng Huang
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
Phase I Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine
The CoVacHGMix adenoviral vector vaccine is a new vaccine developed to protect against SARS-CoV-2 and is a Phase I study designed based on adaptive clinical trial standards.
- Trial name
- NCT05526183
- Testing
- Adeno-viral vector vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
COVID-19
Serological and PCR Testing for COVID-19
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results.
- Trial name
- NCT04404062
- Testing
- Membrane-based immunoassay kit, Quantitative antibody Tests, PCR Test
- Where
- United Kingdom
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Covid19, SARS-CoV2 Infection
Canine COVID-19 Detection Phase 2 and 3
The purpose of this study is to determine whether trained medical detection dogs can accurately detect the presence of COVID-19 in people infected with the virus, or using samples of their clothing or body odour.
- Trial name
- LSH1394 (NCT04948190)
- Testing
- Testing with medical detection dogs
- Where
- United Kingdom
- Volunteers
- 11,015 people, healthy volunteers welcome
- Sponsor
- ARCTEC
COVID-19
SCB-2019 as COVID-19 Vaccine
This is a randomized, double blind, placebo controlled, first-in-human (FIH) study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects.
- Trial name
- NCT04405908
- Testing
- SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
- Where
- Australia
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
SARS-CoV Infection
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04880174
- Testing
- serological testing
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
COVID-19
Serological Surveillance for COVID-19 in Central North Carolina
Background: The SARS-CoV-2 virus has caused a pandemic. Little is known about the virus, so data is needed to form an effective public health response.
- Trial name
- NCT04490174
- Where
- United States
- Volunteers
- 643 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Bioavailability
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.
- Trial name
- NCT05263895
- Testing
- PF-07321332/ritonavir, PF-07321332
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19
Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2
The purpose of this study is to assess the efficacy of Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray as an adjunct treatment of COVID-19.
- Trial name
- NCT04610801
- Testing
- Nasal Spray
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Larkin Community Hospital
SARS-CoV-2 (COVID-19)
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
COVHIC003 is a human infection challenge study in which healthy adults aged 18-50 previously vaccinated with an approved COVID-19 vaccine will be administered a SARS-CoV-2 Omicron EG.5.1 variant given by drops in the nose.
- Trial name
- COVHIC003 (NCT07397455)
- Testing
- SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50, SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50, SARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50
- Where
- 5 sites in United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Imperial College London
SARS-Associated Coronavirus, Covid19
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
- Conditions
- SARS-Associated Coronavirus, Covid19, SARS-CoV Infection
- Trial name
- NCT04468009
- Testing
- Convalescent plasma
- Where
- Argentina
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Hospital de Infecciosas Francisco Javier Muniz
COVID-19, SARS-COV-2 Infection
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation).
- Trial name
- NCT07222384
- Testing
- BNT162b2 (2025/2026 formulation)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Corticosteroids, Covid19
Short Term Corticosteroids in SARS-CoV2 Patients
The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.
- Conditions
- Corticosteroids, Covid19, SARS-CoV 2, Steroids
- Trial name
- NCT04445506
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital
Covid19
Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium
This study will investigate whether pregnant and lactating women can develop similar protective immunity as non-pregnant women against Coronavirus Infectious Disease 2019 (COVID-19) upon vaccination, without safety issues.
- Trial name
- PREGCOVAC (NCT05618548)
- Testing
- COVID-19 vaccine
- Where
- Belgium
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.